Conclusion: CAV1 exacerbates the progression of DCM by suppressing the NRF2/GCLC pathway, suggesting that targeting CAV1 is a potential therapeutic approach for DCM. The gene discussed is GCLC; the disease is familial dilated cardiomyopathy.